Literature DB >> 20193126

Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells.

Yun Jung Park1, Hansoo Lee, Jeong-Hyung Lee.   

Abstract

The function of macrophage inhibitory cytokine-1 (MIC-1) in cancer remains controversial, and its signaling pathways remain poorly understood. In this study, we demonstrate that MIC-1 induces the transactivation of EGFR, ErbB2, and ErbB3 through the activation of c-Src in SK-BR-3 breast cells. MIC-1 induced significant phosphorylation of EGFR at Tyr845, ErbB2 at Tyr877, and ErbB3 at Tyr1289 as well as Akt and p38, Erk1/2, and JNK mitogen-activated protein kinases (MAPKs). Treatment of SK-BR-3 cells with MIC-1 increased the phosphorylation level of Src at Tyr416, and induced invasiveness of those cells. Inhibition of c-Src activity resulted in the complete abolition of MIC-1-induced phosphorylation of the EGFR, ErbB2, and ErbB3, as well as invasiveness and matrix metalloproteinase (MMP)-9 expression in SK-BR-3 cells. Collectively, these results show that MIC-1 may participate in the malignant progression of certain cancer cells through the activation of c-Src, which in turn may transactivate ErbB-family receptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20193126     DOI: 10.5483/bmbrep.2010.43.2.091

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  19 in total

1.  Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.

Authors:  Jayashree P Joshi; Nicole E Brown; Samantha E Griner; Rita Nahta
Journal:  Biochem Pharmacol       Date:  2011-07-23       Impact factor: 5.858

2.  High ErbB3 activating activity in human blood is not due to circulating neuregulin-1 beta.

Authors:  Emmanuel Boateng; Joanne T deKay; Sarah M Peterson; Jacob Boles; Nathan Pinnette; Mary W Sorcher; Michael P Robich; Douglas B Sawyer; Sergey Ryzhov
Journal:  Life Sci       Date:  2020-04-03       Impact factor: 5.037

3.  P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer.

Authors:  S M Donnelly; E Paplomata; B M Peake; E Sanabria; Z Chen; R Nahta
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 4.  Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.

Authors:  R Nahta
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 5.  The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer.

Authors:  Xingya Wang; Seung Joon Baek; Thomas E Eling
Journal:  Biochem Pharmacol       Date:  2012-12-07       Impact factor: 5.858

Review 6.  Concise review: growth differentiation factor 15 in pathology: a clinical role?

Authors:  Jill Corre; Benjamin Hébraud; Philippe Bourin
Journal:  Stem Cells Transl Med       Date:  2013-11-04       Impact factor: 6.940

7.  New developments in the treatment of HER2-positive breast cancer.

Authors:  Rita Nahta
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-05-01

8.  Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer.

Authors:  Rita Nahta
Journal:  ISRN Oncol       Date:  2012-11-22

Review 9.  Cellular functions regulated by phosphorylation of EGFR on Tyr845.

Authors:  Ken-Ichi Sato
Journal:  Int J Mol Sci       Date:  2013-05-23       Impact factor: 5.923

10.  HER2 induces expression of leptin in human breast epithelial cells.

Authors:  Yujin Cha; Youjin Kang; Aree Moon
Journal:  BMB Rep       Date:  2012-12       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.